Tradegate
05.08.25 | 19:23
5,100 Euro
+0,99 % +0,050
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 4,820 | 4,960 | 22:04 | |
| 4,820 | 4,960 | 22:00 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 24.07. | Cantor Fitzgerald reiterates Overweight rating on Rezolute stock | 1 | Investing.com | ||
| 18.07. | Rezolute, Inc. - 8-K, Current Report | 12 | SEC Filings | ||
| 17.07. | Rezolute files to sell 1.3M shares of common stock for holders | 4 | Seeking Alpha | ||
| 09.07. | Rezolute, Inc.: Rezolute Announces Presentation of Participant Baseline Data from its Fully Enrolled Phase 3 Study of Ersodetug in Congenital Hyperinsulinism at the Upcoming Annual Meeting of the Endocrine Society (ENDO 2025) | 3 | GlobeNewswire (USA) | ||
| REZOLUTE Aktie jetzt für 0€ handeln | |||||
| 24.06. | Rezolute ticks higher following disclosure of CFO stock buy | 2 | Seeking Alpha | ||
| 13.06. | Rezolute, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 28.05. | BTIG hält an Kursziel von 15 US-Dollar für Rezolute-Aktie nach Studien-Update fest | 2 | Investing.com Deutsch | ||
| 28.05. | BTIG maintains $15 target on Rezolute stock following trial update | 3 | Investing.com | ||
| 14.05. | Rezolute GAAP EPS of -$0.27 | 2 | Seeking Alpha | ||
| 13.05. | Rezolute, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 13.05. | Rezolute, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 13.05. | Rezolute, Inc.: Rezolute Reports Third Quarter Fiscal 2025 Financial Results and Provides Business Update | 115 | GlobeNewswire (Europe) | sunRIZE enrollment on track including U.S. sites and expected to be completed in May 2025; topline data anticipated in December 2025 U.S. Food and Drug Administration (FDA) grants Breakthrough Therapy... ► Artikel lesen | |
| 25.04. | Rezolute, Inc. Announces Closing of Underwritten Offering | 3 | GlobeNewswire (USA) | ||
| 23.04. | Rezolute Prices $90 Mln Offering With Common Stock And Pre-Funded Warrants | - | RTTNews | ||
| 23.04. | Rezolute 'Thrilled' With Positive Review Of Genetic Disorder Trial, Expects Topline Results In December | 2 | Benzinga.com | ||
| 23.04. | Rezolute gets positive recommendation from IDMC to continue Ersodetug study | 1 | Seeking Alpha | ||
| 23.04. | Rezolute stock rises after pricing $90M securities offering | 1 | Seeking Alpha | ||
| 23.04. | Rezolute kündigt Aktien- und Optionsscheinangebot über 90 Millionen US-Dollar an | 3 | Investing.com Deutsch | ||
| 23.04. | Rezolute, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 23.04. | Rezolute's sunRIZE trial to proceed without changes | 3 | Investing.com |
1 2 Weiter >>
33 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 95,65 | -0,36 % | Ihre wichtigsten Termine: Tyson Foods, Biontech, Adtran, Loews, VDMA und Stabilus stehen heute im Fokus! | © Foto: UnsplashGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Unternehmenstermine 07:00 Uhr, Luxemburg:... ► Artikel lesen | |
| CUREVAC | 4,680 | -0,68 % | CureVac Aktie: BRUTALE PROGNOSE zwingt Anleger zum Handeln. So sollten Sie HEUTE reagieren! | ||
| AMGEN | 244,70 | -5,72 % | Amgen hebt Prognose nach überraschend gut verlaufenem Quartal an | THOUSAND OAKS (dpa-AFX) - Der US-Biotechkonzern Amgen blickt nach einem überraschend gut gelaufenen Quartal optimistischer auf 2025. Der Umsatz dürfte bei 35 bis 36 Milliarden US-Dollar liegen, teilte... ► Artikel lesen | |
| NOVAVAX | 6,450 | +10,65 % | Novavax, Inc.: Novavax Reports Second Quarter 2025 Financial Results and Operational Highlights | Total revenue of $239 million in the second quarter of 2025
Received FDA BLA approval for Nuvaxovid, the only recombinant protein-based, non-mRNA COVID-19 vaccine... ► Artikel lesen | |
| BIOGEN | 111,15 | -3,26 % | Biogen-Aktie: Kurs mit wenig Bewegung (114,5994 €) | Im US-amerikanischen Wertpapierhandel ist das Wertpapier von Biogen derzeit unauffällig. Die Aktie kostete zuletzt 132,69 US-Dollar. Ein geringes Kursplus von 0,38 Prozent zeigt die Kurstafel für die... ► Artikel lesen | |
| MAINZ BIOMED | 1,480 | -1,99 % | Mainz BioMed NV: Mainz Biomed Announces Pricing of $3.0 Million Follow-On Offering of Ordinary Shares and Warrants | BERKELEY, Calif. and MAINZ, Germany, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the... ► Artikel lesen | |
| VIKING THERAPEUTICS | 26,945 | -8,33 % | Is Viking Therapeutics the Next Big Biotech Bet? | ||
| INTELLIA THERAPEUTICS | 9,700 | -2,92 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | CAMBRIDGE, Mass., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies... ► Artikel lesen | |
| GENMAB | 181,75 | -5,07 % | Genmab A/S: Genmab Announces Net Sales of DARZALEX (daratumumab) for Second Quarter of 2025 | Company Announcement Net sales of DARZALEX® in the second quarter of 2025 totaled USD 3,539 millionGenmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 7,380 | +2,07 % | BioCryst Pharmaceuticals, Inc.: BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | RESEARCH TRIANGLE PARK, N.C., Aug. 06, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted... ► Artikel lesen | |
| TEMPUS AI | 47,600 | -4,80 % | If You'd Invested $1,000 in Tempus AI Stock (TEM) 1 Year Ago, Here's How Much You'd Have Today | ||
| SAREPTA THERAPEUTICS | 13,970 | -3,42 % | Sarepta-Aktie: +87,8% über Nacht - Sharedeals-Leser feiern | Bei Sarepta Therapeutics explodiert der Kurs innerhalb von wenigen Stunden nach einem exklusiven Tipp auf sharedeals.de. Was steckt hinter dem Coup - und wie findest Du den nächsten Depot-Turbo? Gideon... ► Artikel lesen | |
| CARDIOL THERAPEUTICS | 0,920 | -20,96 % | Cardiol Therapeutics Inc.: Cardiol Therapeutics Announces Topline Results from the Phase II ARCHER Trial of CardiolRx in Acute Myocarditis | Change in the primary endpoint of left ventricular (LV) extracellular volume (ECV) showed a notable improvement (p = 0.0538) favouring CardiolRx over placebo.Reduction in ECV was associated with improvements... ► Artikel lesen | |
| EXELIXIS | 32,290 | -0,22 % | Exelixis, Inc.: Exelixis' Partner Ipsen Receives European Commission Approval for CABOMETYX (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors | - Approval is based on the phase 3 CABINET pivotal trial, in which CABOMETYX demonstrated a statistically significant and clinically meaningful improvement in progression-free survival versus placebo... ► Artikel lesen | |
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,178 | -3,70 % | Nature Methods Paper Leverages PacBio Sequencing Technology to Develop the Platinum Pedigree Benchmark, a New Standard for Accurate Characterization of Variation in the Human Genome that Improves Training for AI Models |
REZOLUTE INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von +0,050 (+0,99 %) liegt der Kurs bei 5,100 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu REZOLUTE INC finden Sie auf Wallstreet Online.